Companies
/Healthcare
Pfizer Inc
$27.51
▼ $0.55 (−1.95%) today
Markets open · 3:23pm ET
Pfizer (PFE) Earnings History & Trends
100%
EPS beat rate
+26.78%
Avg. EPS surprise
Consecutive EPS beats
PFE vs Market · 30-day return after each reportPFES&P 500
PFE EPS Trend · estimate vs actualEstimateActual
PFE Revenue Trend · estimate vs actualEstimateActual
How Often Does Pfizer Beat Earnings Estimates?
Pfizer beat EPS estimates in 8 of its last 8 reported quarters, and has beaten 8 quarters in a row.
| Quarter | EPS · est. | Surprise | Revenue · est. | Surprise |
|---|---|---|---|---|
| Q3 2026 Adjusted results include a one-time $650 million Acquired In-Process R&D charge related to the Innovent Biologics in-licensing and collaboration agreement (approximately $0.10 unfavorable impact). GAAP diluted EPS of $0.56 additionally reflects $1,128 million amortization of intangible assets and $791 million restructuring charges and certain acquisition-related costs. | $0.87 est. $0.73 | +19.51% | $16.6B est. $15.9B | +4.45% |
| Q2 2026 | $0.77 est. $0.68 | +12.87% | $15.0B est. $14.4B | +4.49% |
| Q1 2026 | $0.75 est. $0.52 | +44.23% | $14.5B est. $13.8B | +4.70% |
| Q4 2025 | $0.66 est. $0.57 | +15.79% | $17.6B est. $16.9B | +4.09% |
| Q3 2025 | $0.87 est. $0.63 | +38.10% | $16.7B est. $16.5B | +0.92% |
| Q2 2025 | $0.78 est. $0.57 | +36.84% | $14.7B est. $13.5B | +8.29% |
| Q1 2025 | $0.92 est. $0.67 | +37.31% | $13.7B est. $14.1B | −2.69% |
| Q4 2022 | $1.14 est. $1.04 | +9.62% | $24.3B est. $24.3B | +0.02% |
Figures from SEC filings and company reports. Not investment advice.